SCHEDULE 13G/A: Goldman Sachs Files Amended Schedule 13G for Kiora Pharmaceuticals, Disclosing Negligible Passive Stake
Beneficial Ownership Statement
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, confirming a passive beneficial ownership of 130 shares, representing 0.0% of Kiora Pharmaceuticals, Inc.'s common stock as of December 31, 2024.
Summary
- The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Kiora Pharmaceuticals, Inc.
- As of December 31, 2024, the reporting persons collectively beneficially own 130 shares of Kiora Pharmaceuticals, Inc. Common Stock, par value $0.01 per share.
- This ownership represents 0.0% of the total class of securities.
- The shares are held with shared voting power and shared dispositive power of 130 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- Goldman Sachs & Co. LLC, a registered broker or dealer and investment adviser, is a subsidiary of The Goldman Sachs Group, Inc. and is the entity through which the securities are owned or deemed beneficially owned.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing disclosing a negligible passive ownership stake. It contains no information that would significantly alter the perception of Kiora Pharmaceuticals' financial health or prospects, nor does it indicate any strategic intent from the reporting entity beyond ordinary course of business.
Positives
- A major financial institution, Goldman Sachs, holds a stake, albeit negligible, in Kiora Pharmaceuticals, indicating it is part of their ordinary course of business holdings.
Negatives
- The beneficial ownership of 130 shares represents 0.0% of the class, indicating a negligible stake that does not suggest significant institutional interest or confidence in Kiora Pharmaceuticals.
Risks
- The document does not disclose any specific risks related to Kiora Pharmaceuticals, Inc.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Kiora Pharmaceuticals, Inc.'s future performance or strategic direction.
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Ameen Soetan, Attorney-in-fact for Goldman Sachs)
Industry Context
This filing is a routine disclosure of beneficial ownership by a large financial institution. It does not provide specific insights into broader industry trends for the pharmaceutical sector or Kiora Pharmaceuticals' competitive position, beyond indicating that the company's stock is part of Goldman Sachs' ordinary course of business holdings.
Stakeholder Impact
- The impact on shareholders is negligible as the reported ownership stake is 0.0% and does not suggest any significant change in institutional interest or control.
Key Dates
| Date | Description |
|---|---|
| 2023-12-01 | Date of the Power of Attorney for Goldman Sachs & Co. LLC that was superseded by a new one on October 1, 2024. |
| 2024-02-09 | Date of the Power of Attorney for The Goldman Sachs Group, Inc. that was superseded by a new one on July 29, 2024. |
| 2024-07-29 | Effective date of the new Power of Attorney for The Goldman Sachs Group, Inc., which remains in effect until July 29, 2025. |
| 2024-10-01 | Effective date of the new Power of Attorney for Goldman Sachs & Co. LLC, which remains in effect until October 1, 2025. |
| 2024-12-31 | Date of the event which required the filing of this Schedule 13G statement (beneficial ownership snapshot date). |
| 2025-01-28 | Date the Schedule 13G statement was signed by Ameen Soetan, Attorney-in-fact for both Goldman Sachs entities. |
| 2025-07-29 | Expiration date of the Power of Attorney for The Goldman Sachs Group, Inc., unless revoked earlier. |
| 2025-10-01 | Expiration date of the Power of Attorney for Goldman Sachs & Co. LLC, unless revoked earlier. |
Keywords
Schedule 13G, Beneficial Ownership, Goldman Sachs, Kiora Pharmaceuticals, Common Stock, SEC Filing, Institutional Ownership, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.